QPPV.COM KNOWLEDGE ASSESSMENT

Secukinumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Secukinumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why does the distinction between ligand neutralisation and cell depletion matter in pharmacovigilance assessment?

It helps define which immune functions are directly altered and prevents assuming broad lymphocyte loss It proves that infections cannot be related to treatment It means that immunogenicity is impossible with secukinumab It eliminates the need to consider concomitant immunosuppressive therapy

Question 2 of 10 Which biological explanation best accounts for mucocutaneous candidiasis during IL-17A inhibition?

IL-17A contributes to antifungal mucosal defence and epithelial barrier immunity Secukinumab directly acts as a nutrient source for Candida species IL-17A inhibition causes universal depletion of neutrophils Candidiasis is expected because all monoclonal antibodies directly damage mucosa

Question 3 of 10 Which aggregate-review strategy is most likely to detect a clinically meaningful IBD signal associated with secukinumab?

Retrieve gastrointestinal cases and refine them into new-onset Crohn's disease, new-onset ulcerative colitis and exacerbation of established disease Pool all diarrhoea terms without reviewing clinical narratives Exclude cases with pre-existing gastrointestinal disease Review only cases that resulted in death

Question 4 of 10 Why should aggregate safety analyses stratify secukinumab cases by indication?

Different indications can have different baseline risks, disease activity, treatment goals and concomitant therapies The molecular identity of secukinumab changes according to the indication Indication is relevant only for efficacy and has no effect on safety interpretation Stratification is needed only for paediatric cases and not for adult diseases

Question 5 of 10 Which information is most important for evaluating a report of neutropenia during secukinumab treatment?

Baseline and nadir absolute neutrophil counts, infection status, concomitant medicines and recovery over time Only the patient's diagnosis before beginning treatment Only the presence or absence of an injection-site reaction The number of previous skin lesions without laboratory results

Question 6 of 10 Which report would provide the strongest mechanistic information for assessing candidiasis associated with secukinumab?

A recurrent oesophageal Candida infection confirmed clinically or microbiologically, with treatment chronology documented An undifferentiated report stating only that the patient had an infection A report of self-limited headache after an injection A report of chronic psoriasis without any infectious symptoms

Question 7 of 10 Which statement correctly distinguishes hepatitis B exposure from hepatitis B reactivation?

A positive hepatitis B core antibody indicates prior exposure but does not by itself establish virologically confirmed reactivation Any positive hepatitis B core antibody result proves active reactivation Reactivation can be diagnosed without considering baseline serology or viral load Hepatitis B status is irrelevant if the patient has no current liver symptoms

Question 8 of 10 Why is biological-product and batch traceability important for secukinumab reports?

It supports investigation of product-quality or presentation-related clusters and prevents inappropriate aggregation across non-identical biological products It is needed only to calculate the patient's body weight It replaces the need to record the indication and treatment chronology It proves that every adverse event is caused by a manufacturing problem

Question 9 of 10 Which follow-up detail is particularly important in a suspected lack-of-efficacy case involving self-administration?

Whether the intended dose was fully delivered, whether leakage occurred, storage was appropriate and injection technique was correct Only the colour of the packaging Only whether the patient reported mild injection-site discomfort Whether the patient had ever used a topical therapy

Question 10 of 10 Which statement best describes the pharmacovigilance implications of paediatric secukinumab exposure?

Age, weight, indication, vaccination history, dosing chronology and caregiver administration can materially affect case interpretation Paediatric cases can be pooled with adults because the active molecule is identical Only the child's sex is needed to interpret paediatric safety cases Paediatric exposure eliminates the relevance of concomitant immunomodulatory therapy

Secukinumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance

Cookie Settings